Review
Gastroenterology & Hepatology
Manon Allaire, Marika Rudler, Dominique Thabut
Summary: The review highlights the complications of portal hypertension and hepatocellular carcinoma in cirrhosis patients, emphasizing the challenges in treatment when both conditions coexist. Studies suggest that the combination of Atezolizumab and Bevacizumab may impact portal hypertension levels and related complications, but real-life data are lacking to support this. Management of portal hypertension remains crucial to improve outcomes for patients with hepatocellular carcinoma.
LIVER INTERNATIONAL
(2021)
Article
Medicine, General & Internal
Gianluca Vadala, Luca Ambrosio, Caterina Cattani, Roberta Bernardini, Antonino Giacalone, Rocco Papalia, Vincenzo Denaro
Summary: The study demonstrated that intra-articular bevacizumab treatment significantly reduced cartilage degeneration and synovial OA changes, effectively arresting OA progression. The most efficacious dose was found to be 20 mg, leading to increased production of type 2 collagen and aggrecan content even higher than in healthy cartilage.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Peripheral Vascular Disease
Julia C. F. Quintanilha, Yingmiao Liu, Amy S. Etheridge, Akram Yazdani, Hedy L. Kindler, William Kevin Kelly, Andrew B. Nixon, Federico Innocenti
Summary: This study identified plasma proteins associated with an increased risk of severe bevacizumab-induced hypertension, indicating the potential value of these proteins in predicting hypertension in patients. Lower levels of angiopoietin-2, VEGF-A, and VCAM-1 were found to be independently associated with grade 3 hypertension, providing evidence for their predictive capabilities.
Article
Oncology
Miyuki Nakagawa, Masanori Inoue, Sadahisa Ogasawara, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yotaro Iino, Masamichi Obu, Yuki Haga, Atsuyoshi Seki, Yasuharu Kikuchi, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Takashi Taida, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Kenji Ito, Hideaki Mizumoto, Masami Shinozaki, Jun Kato, Naoya Kato
Summary: This study investigated the long-term efficacy and adverse events of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma. It found that the median progression-free survival (PFS) for the first-line treatment group was 8.0 months, while the median PFS for the second- or later-line treatment group was 4.1 months, significantly worse than the first-line treatment group. Interrupted bevacizumab treatment, mainly due to proteinuria, was more common in patients with hypertension and/or diabetes mellitus. The landmark analysis suggested that the interruption of bevacizumab may be associated with impaired efficacy of atezolizumab plus bevacizumab over the long term.
Article
Ophthalmology
M. Elizabeth Hartnett, David K. Wallace, Trevano W. Dean, Zhuokai Li, Charline S. Boente, Eniolami O. Dosunmu, Sharon F. Freedman, Richard P. Golden, Lingkun Kong, S. Grace Prakalapakorn, Michael X. Repka, Lois E. Smith, Haibo Wang, Raymond T. Kraker, Susan A. Cotter, Jonathan M. Holmes
Summary: The results of this phase 1 dose de-escalation case series study showed that intravitreal bevacizumab at low doses reduced plasma VEGF levels in infants with severe retinopathy of prematurity. However, there was no association between the total dose of bevacizumab administered and the reduction in plasma VEGF levels.
JAMA OPHTHALMOLOGY
(2022)
Article
Health Care Sciences & Services
Guo-Shi Lin, Wei-Wei Wang, Hong Lin, Rui-Sheng Lin
Summary: This study retrospectively analyzed the clinical data of 156 patients who underwent glioma surgery to examine the influences of bevacizumab combined with intensity-modulated radiation therapy (IMRT) on postoperative brain glioma. The results showed that bevacizumab combined with IMRT significantly improved clinical efficacy, reduced serum marker levels, and improved cognitive function, without significant impact on coagulation function.
JOURNAL OF HEALTHCARE ENGINEERING
(2022)
Article
Nutrition & Dietetics
Somin Lee, Cheolmin Jo, Ho-Young Choi, Kyungjin Lee
Summary: The combined administration of curcumin and amlodipine showed a stronger vasorelaxant effect than amlodipine alone, but did not significantly reduce systolic and diastolic blood pressure compared to amlodipine alone.
Article
Pharmacology & Pharmacy
Chenyang Shi, Jiaxin Li, Guorong Fan, Yu Liu
Summary: This study proposes a synergistic antitumour strategy by simultaneously blocking VEGF and CD47 signalling to enhance the therapeutic effect of bevacizumab on advanced gastric cancer. The results demonstrate that this strategy can reverse immune-related resistance, enhance antitumour effects, and inhibit tumour metastasis.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Ophthalmology
Sadik Etka Bayramoglu, Nihat Sayin
Summary: This study investigated the effect of intravitreal bevacizumab on retinal vascularization progression and found that the ratio of FD to DD decreased significantly with increasing age. The additional treatment rate and progression of retinal vascularization were similar between the groups in terms of FD units, but there was a higher difference in LTRV by DD units in the low dose group.
Article
Oncology
Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Kenichi Yoshimura, Shigehisa Kitano, Toshimi Takano
Summary: This study investigated the use of nivolumab, bevacizumab, and paclitaxel triple therapy for metastatic breast cancer. The results showed promising efficacy and manageable toxicity of this treatment in the first-line setting.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Melissa M. Hardesty, Thomas C. Krivak, Gail S. Wright, Erika Hamilton, Evelyn L. Fleming, Jimmy Belotte, Erika K. Keeton, Ping Wang, Divya Gupta, Aine Clements, Heidi J. Gray, Gottfried E. Konecny, Richard G. Moore, Debra L. Richardson
Summary: This study evaluated the safety and efficacy of Niraparib + bevacizumab as a first-line maintenance therapy for newly diagnosed advanced ovarian cancer patients. The results showed promising PFS outcomes and the safety profile was consistent with the monotherapy of these drugs.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Maria M. Rubinstein, Shannan Dickinson, Priyanka Narayan, Qin Zhou, Alexia Iasonos, Weining Ma, Yulia Lakhman, Vicky Makker
Summary: The study reviewed the use of bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer, finding that it was associated with modest clinical efficacy and remains a viable palliative option in heavily pretreated patients.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Jingxue Zhang, Xuejing Yan, Rui Liu, Shen Wu, Qian Liu, Jing Li, Jianmin Ma
Summary: This study examined the efficacy of the antiangiogenic drug bevacizumab in a LGACC patient-derived xenograft (PDX) animal model. The results showed that bevacizumab could inhibit PDX tumor growth, reduce the expression of neovascularization-related proteins, and has potential for LGACC treatment.
CANCER MANAGEMENT AND RESEARCH
(2022)
Article
Medicine, General & Internal
Caroline Foch, Jan Feifel, Ulrike Gottwald-Hostalek
Summary: This study compared the effects of a low-dose combination of amlodipine and bisoprolol with up titration to maximum dose of amlodipine on blood pressure in hypertensive patients. The findings showed a greater decrease in diastolic blood pressure with the low-dose combination therapy.
CURRENT MEDICAL RESEARCH AND OPINION
(2022)
Review
Oncology
Domenico Ribatti, Antonio Giovanni Solimando, Francesco Pezzella
Summary: Several anti-angiogenic drugs are approved for cancer treatment, but resistance and adverse effects may occur. Combining multiple anti-angiogenic molecules or using them in combination with other treatment regimens is indicated as alternative therapeutic strategies to overcome resistance. Comprehensive omics profiling is crucial for increasing clinical benefits and overcoming resistance to anti-angiogenic therapies.
Review
Pharmacology & Pharmacy
Ali N. Chamseddine, Tarek Assi, Olivier Mir, Salem Chouaib
Summary: The plasticity and diversity of tumor-associated macrophages (TAM) play essential roles in cancer progression. TAM can shift their polarization in response to tumor microenvironment cues, promoting or halting cancer development. However, TAM's immunosuppressive functions contribute to resistance to immune checkpoint inhibitors (ICI). Targeting TAM modulation in combination with ICI shows potential for optimizing ICI efficacy.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Hematology
Isabelle Mahe, Giancarlo Agnelli, Cihan Ay, Aristotelis Bamias, Cecilia Becattini, Marc Carrier, Celine Chapelle, Alexander T. Cohen, Philippe Girard, Menno Huisman, Frederikus A. Klok, Juan J. Lopez-Nunez, Anthony Maraveyas, Didier Mayeur, Olivier Mir, Manuel Monreal, Marc Righini, Charles M. Samama, Kostas Syrigos, Sebastian Szmit, Adam Torbicki, Peter Verhamme, Eric Vicaut, Tzu-Fei Wang, Guy Meyer, Silvy Laporte
Summary: The API-CAT study aims to evaluate whether a reduced-dose regimen of apixaban is noninferior to a full-dose regimen in preventing recurrent VTE in cancer patients. This international, randomized, double-blind trial will assess VTE events as the primary efficacy outcome and clinically relevant bleeding as the principal safety endpoint.
THROMBOSIS AND HAEMOSTASIS
(2022)
Editorial Material
Oncology
E. Minvielle, M. di Palma, O. Mir, F. Scotte
ANNALS OF ONCOLOGY
(2022)
Editorial Material
Oncology
B. C. Ozdemir, S. Oertelt-prigione, A. A. Adjei, S. Borchmann, J. B. Haanen, A. Letsch, O. Mir, A. Quaas, R. H. A. Verhoeven, A. D. Wagner
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
E. Palassini, O. Mir, G. Grignani, B. Vincenzi, H. Gelderblom, A. Sebio, C. Valverde, G. G. Baldi, A. Brunello, G. G. Cardellino, A. Marrari, G. Badalamenti, J. Martin-Broto, V Ferraresi, M. Libertini, S. Turano, I Gataa, P. Collini, A. P. Dei Tos, M. Gennaro, F. Bini, S. Provenzano, S. Lo Vullo, L. Mariani, A. Le Cesne, P. G. Casali
Summary: This study retrospectively reviewed the outcomes of systemic treatments in 56 female patients with advanced breast PT. The results showed that anthracyclines plus ifosfamide (AI) had a higher response rate, but the median progression-free survival was only 5.7 months.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Bruno Vincenzi, Andrea Napolitano, Marta Fiocco, Olivier Mir, Piotr Rutkowski, Jean-Yves Blay, Peter Reichardt, Heikki Joensuu, Elena Fumagalli, Spyridon Gennatas, Nadia Hindi, Margherita Nannini, Mariella Spalato Ceruso, Antoine Italiano, Giovanni Grignani, Antonella Brunello, Silvia Gasperoni, Tommaso De Pas, Giuseppe Badalamenti, Maria A. Pantaleo, Winan J. van Houdt, Nikki S. IJzerman, Neeltje Steeghs, Hans Gelderblom, Ingrid M. E. Desar, Johanna Falkenhorst, Marianna Silletta, Marta Sbaraglia, Giuseppe Tonini, Javier Martin-Broto, Peter Hohenberger, Axel Le Cesne, Robin L. Jones, Angelo P. Dei Tos, Alessandro Gronchi, Sebastian Bauer, Paolo G. Casali
Summary: This study evaluated the effect of high-dose imatinib on the survival of patients with KIT exon 9-mutated gastrointestinal stromal tumors. The results showed that increasing the dose from 400 mg/day to 800 mg/day did not lead to better survival outcomes.
CLINICAL CANCER RESEARCH
(2022)
Editorial Material
Immunology
Tarek Assi, Olivier Mir
Article
Oncology
E. F. Nassif, J-Y Blay, C. Massard, A. Dufresne, M. Brahmi, P. Cassier, I Ray-Coquard, P. Pautier, A. Leary, M-P Sunyach, R. Bahleda, A. Levy, C. Le Pechoux, C. Honore, O. Mir, A. Le Cesne
Summary: This study retrospectively analyzed prognostic factors for progression-free survival (PFS) in patients with advanced soft-tissue sarcomas participating in early phase trials. The study found that myxoid liposarcoma, ≥2 prior lines of treatment, liver metastasis, and RMH score >2 were independent prognostic factors for shorter PFS, while leiomyosarcoma, molecular screening, and histology-driven screening were associated with improved PFS.
Article
Oncology
Sarah Watson, Benjamin Verret, Stanislas Ropert, Julien Adam, Rastislav Bahleda, Sylvain Briand, Andrea Cavalcanti, Ali N. Chamseddine, Charles Court, Elie Fadel, Matthieu Faron, Leila Haddag-Miliani, Clemence Henon, Cecile Le Pechoux, Antonin Levy, Olaf Mercier, Carine Ngo, Charles Honore, Axel Le Cesne, Olivier Mir
Summary: The activity of single-agent gemcitabine in advanced angiosarcoma was evaluated in this study. The results showed that gemcitabine had clinically meaningful activity, especially in cardiac angiosarcoma and patients who had received prior treatments.
Article
Oncology
Ruth Gabriela Herrera-Gomez, Miruna Grecea, Claire Gallois, Valerie Boige, Patricia Pautier, Barbara Pistilli, David Planchard, David Malka, Michel Ducreux, Olivier Mir
Summary: This study retrospectively evaluated the safety and efficacy of combining bevacizumab and chemotherapy in adult cancer patients with inflammatory bowel disease. The results showed that the combination treatment was safe in patients with quiescent or moderately active inflammatory bowel disease.
Article
Oncology
Anne-Sophie Michallet, Stephanie Malartre, Elodie Vignaud, Alexiane Bocquet, Pascale Sontag, Christelle Galvez, Jean-Yves Blay, Pierre Heudel, Alexandre Vimont, Martin Blachier, Marie Ferrua, Etienne Minvielle, Olivier Mir
Summary: This study evaluates the cost-effectiveness of an Ambulatory Medical Assistance (AMA) programme in patients with haematological malignancies. The results show that the AMA programme is cost-effective compared to a simulated control arm with no intervention.
EUROPEAN JOURNAL OF CANCER CARE
(2022)
Review
Health Care Sciences & Services
E. Minvielle, A. Fierobe, A. Fourcade, M. Ferrua, M. di Palma, F. Scott, O. Mir
Summary: This study examines the use of patient-reported measures (PRMs) as quality indicators (QIs) for health policy purposes, focusing on the field of oncology. The research analyzed 61 articles and 19 websites/reports, identifying 29 patient-reported experience measures (PREMs) and 48 patient-reported outcome measures (PROMs) from multiple countries. The study found that there are still barriers to overcome before PRMs can be effectively used for health policy in oncology, and further research is needed to develop valid QIs on a national level.
Article
Oncology
Alice Boileve, Laurence Albiges, Michel Ducreux, Eric Baudin, Alexandra Leary, Benjamin Besse, Julien Hadoux, David Malka, Andre Rieutord, Florian Scotte, Amandine Maulard, Olivier Mir
Summary: This study retrospectively investigated the safety of concomitant use of DOAC and anti-VEGF agents in cancer patients. The results showed that the use of DOAC was safe in selected patients treated with KI, but the safety with bevacizumab was unclear. More data are needed to establish guidelines for this specific group of patients.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
P. Gougis, A. Geraud, M. Hilmi, A. Vozy, L. Campedel, B. Abbar, C. Allio, S. De Chatillon, A. Portalier, F. Lapray, S. Choquet, J. -P. Spano, F. Reyal, O. Mir, C. Funck-Brentano, A. -S. Hamy
Summary: This study aimed to assess the feasibility of self-assessment of herb, food, and dietary supplement interactions with cancer treatment in patients. The results showed that self-assessment using an application could detect possible interactions, and further prospective interventional studies are recommended to evaluate the clinical benefits of this approach.
Article
Radiology, Nuclear Medicine & Medical Imaging
Mickael Tordjman, Charles Honore, Amandine Crombe, Amine Bouhamama, Antoine Feydy, Laurent Dercle, Leila Haddag, Pierre-Alban Bouche, Carine Ngo, Axel Le Cesne, Jean-Yves Blay, Olivier Mir, Mehdi Brahmi, Charlotte Martin, Marie Karanian, Samy Ammari, Michele Kind, Virginie Audard, Francois Le Loarer, Behnam Rabiee, Antoine Italiano, Pascaline Boudou-Rouquette, David Biau, Corinne Balleyguier, Frederique Larousserie, Jean-Luc Drape, Fadila Mihoubi
Summary: This study demonstrated that imaging biomarkers can be used to predict long-term outcome in patients with synovial sarcomas. Strikingly, the presence of calcifications on CT scan is associated with favorable outcome and provides an incremental value over existing prognostic factors such as age, grade, and size.
EUROPEAN RADIOLOGY
(2023)